Last Updated on October 14, 2024 by The Health Master
Arthritis
Millions of people in India rely on medication to manage rheumatoid arthritis, a chronic autoimmune disease.
The recent case of Artamin 250mg capsules, a key medication for this condition, highlights the complexities of drug pricing regulations and their impact on patient access.
Price Fixation
Maharashtra-based VHB Life Sciences Ltd., the manufacturer of Artamin, has successfully challenged the National Pharmaceutical Pricing Authority’s (NPPA) decision on the drug’s ceiling price.
The company argued that the NPPA failed to consider their implemented price revisions while calculating the ceiling price.
Missed Representation Window
VHB Life Sciences claims they adhered to the Drugs Prices Control Order (DPCO) 2013 by revising the Maximum Retail Price (MRP) and Price to Retailer (PTR) based on the Wholesale Price Index (WPI).
However, the company maintains that the NPPA overlooked their revised PTR during the price fixation process.
Review Authority Orders Recalculation
The Department of Pharmaceuticals (DoP), acting as the review authority, acknowledged VHB Life Sciences’ argument.
The DoP noted that while the company missed the 10-day window to file a representation against the draft ceiling price, they fulfilled all other DPCO requirements.
Similar Cases Prompt Review
This isn’t an isolated incident. The DoP made similar observations in recent petitions by RPG Life Sciences concerning antiviral and blood pressure medications.
These cases suggest a potential need for revising the DPCO’s representation window policy to ensure fairness for pharmaceutical companies that comply with regulations.
Potential Impact on Patients
A recalculated ceiling price for Artamin could lead to either an increase or decrease in the drug’s cost.
This decision will directly impact the affordability of this essential medication for patients with rheumatoid arthritis.
Looking Ahead
The DoP’s intervention highlights the ongoing debate between ensuring affordable medication for patients and encouraging pharmaceutical companies to invest in research and development.
Striking a balance between these two priorities is crucial for a sustainable healthcare system in India.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
NPPA revises ceiling price of Asthma Inhaler Combination
NPPA revised Ceiling price of 1 scheduled formulation: May 2024
NPPA revised Ceiling price of 6 scheduled formulations: May 2024
NPPA fixed retail price of 4 formulations: May 2024
NPPA fixed retail price of 37 formulations: May 2024
NPPA fixed Ceiling price of 6 scheduled formulations: February 2024
New Schedule M: Impact on Cosmetic Manufacturing
DCGI approval granted for this new Antibiotic Drug Combination
Gujarat FDCA Cracks Down on Medical Stores: Licenses cancelled
Gujarat FDCA Cracks Down on Pharmaceutical Manufacturing Violations
CDSCO Panel Approves Benralizumab Solution For Injection In Auto-Injector
BIS Standards for Medical Device Testing in India
NABL Clarifies Test Method for Blood-Resistant PPE
Govt issues instructions on marketing codes of pharma companies
Nutraceuticals in Drug Units: Panel to examine the issue
CDSCO underscores stringent compliance to Revised Schedule M
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
